This site is intended for healthcare professionals
News

European Commission approves Oxlumo an RNAi therapeutic, to treat primary hyperoxaluria type 1.- Alnylam Pharma

Read time: 1 mins
Last updated:20th Nov 2020
Published:20th Nov 2020
Condition: Hyperoxaluria
Type: drug
Register free for full access to medthority.com